Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $22.00 by Analysts at Wedbush

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target cut by Wedbush from $25.00 to $22.00 in a research report report published on Wednesday,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently weighed in on the stock. Canaccord Genuity Group raised their target price on shares of Ultragenyx Pharmaceutical from $37.00 to $39.00 and gave the company a “buy” rating in a report on Friday, September 18th. Barclays upped their price target on shares of Ultragenyx Pharmaceutical from $32.00 to $35.00 and gave the company an “overweight” rating in a report on Monday, September 21st. Cantor Fitzgerald increased their price target on shares of Ultragenyx Pharmaceutical from $33.00 to $39.00 and gave the company an “overweight” rating in a research report on Friday, September 18th. Guggenheim lowered their price target on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, August 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, October 6th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Hold” and a consensus price target of $30.47.

Ultragenyx Pharmaceutical Stock Up 3.2%

Shares of RARE stock opened at $17.16 on Wednesday. Ultragenyx Pharmaceutical has a fifty-two week low of $12.73 and a fifty-two week high of $39.89. The stock has a market cap of $1.69 billion, a P/E ratio of -3.31 and a beta of 0.37. The business has a fifty day simple moving average of $16.45 and a 200-day simple moving average of $22.78.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($0.06). The firm had revenue of $173.00 million during the quarter, compared to analyst estimates of $182.49 million. During the same period in the previous year, the business earned ($1.81) earnings per share. The firm’s revenue was up 8.2% on a year-over-year basis. On average, sell-side analysts anticipate that Ultragenyx Pharmaceutical will post -4.30 earnings per share for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 7,066 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $15.27, for a total transaction of $107,897.82. Following the sale, the chief financial officer owned 89,229 shares of the company’s stock, valued at $1,362,526.83. This trade represents a 7.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 8,510 shares of company stock worth $127,561 over the last quarter. 5.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in Ultragenyx Pharmaceutical in the 2nd quarter valued at $355,746,000. Bank of America Corp DE purchased a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth $38,347,000. Jefferies Financial Group Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth $31,040,000. Eagle Health Investments LP acquired a new stake in shares of Ultragenyx Pharmaceutical during the first quarter worth $18,522,000. Finally, Palo Alto Investors LP acquired a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth $19,916,968. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx reaffirmed its 2026 revenue and 2027 profitability outlook. It also said expense reductions are expected to cut 2027 R&D spending by at least 50% versus 2025, and it has agreements to sell two priority review vouchers for a combined $413 million. The company also reported FDA approval of GENGLYCOS and FAYUVI in the third quarter. Company earnings release
• Neutral Sentiment: Analyst actions were mixed. TD Cowen raised its target to $19 and kept a Buy rating; Canaccord cut its target to $34 but retained Buy. Morgan Stanley raised its target to $22 with an Equal Weight rating, while Goldman Sachs and Wedbush lowered targets to $17 and $22, respectively, and kept neutral ratings. Analyst ratings
• Negative Sentiment: Third-quarter revenue was $173 million, up 8.2% year over year but below the $182.49 million consensus. The $1.16-per-share loss also missed estimates of $1.10. A Seeking Alpha analysis additionally flagged reliance on CRYSVITA, limited contributions from newer launches, and pipeline setbacks; it argued the profitability pivot depends heavily on deep R&D cuts. Seeking Alpha analysis

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.